Added to YB: 2026-06-23
Pitch date: 2026-06-20
ACHV [bullish]
Achieve Life Sciences, Inc.
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
Market Cap
$497.9M
Pitch Price
N/A
Price Target
14.50 (+161%)
Dividend
N/A
EV/EBITDA
-9.28
P/E
-4.50
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Can we Achieve success ($ACHV)?
ACHV: One-drug biotech for cytisinicline (smoking/vaping cessation). PT $14.50 (+170% from $5.36). June 20 PDUFA CRL already priced in (mfg, not data). Real catalyst: Q4'26 NDA resubmission w/Adare + pre-approval inspection, H1'27 launch. Strong Phase 3 data (32.6% vs 7% abstinence), clean safety vs Chantix. ~$198M pro-forma cash, runway past 2028, ~$2.50 cash floor. Bull $22, bear $1.50-2. Peak rev ~$394M base (4.5% share).
Read full article (6 min)